BTIG Reiterates Buy on Avalo Therapeutics, Maintains $40 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.3%

Neg 0% Neu 89.3% Pos 0%

BTIG analyst Julian Harrison reiterates Avalo Therapeutics (NASDAQ:AVTX) with a Buy and maintains $40 price target.

Comments

No comments yet. Be the first!